FMP
Forward Pharma A/S
FWP
NASDAQ
Inactive Equity
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.
1.95 USD
0 (0%)
About
ceo
Mr. Claus Svendsen
sector
Healthcare
industry
Biotechnology
website
https://www.forward-pharma.com
exchange
NASDAQ
Description
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.
CIK
0001604924
ISIN
US34986J2042
CUSIP
34986J105
Address
Oestergade 24A, 1, Copenhagen ...
Phone
4533444242
Country
DK
Employee
4
IPO Date
Oct 15, 2014
Summary
CIK
0001604924
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
34986J105
ISIN
US34986J2042
Country
DK
Price
1.95
Beta
0
Volume Avg.
9.84k
Market Cap
0
Shares
-
52-Week
1.43-6.2797
DCF
13.2
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
0
P/B
-
Website
https://www.forward-pharma.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest FWP News
It looks like there's no news available.
